10-Q · May 7, 2026
Xenon Pharmaceuticals reported Q1 2026 results with no revenue generated, significantly falling short of the estimated $3.8 million. The reported EPS of -$1.17 was better than the anticipated -$1.19. The company plans…
XENE earnings analysis
10-Q · Filed November 9, 2026 · Our reading of the company's report
The latest report
Xenon continues to operate as a development-stage biotechnology company with $0 revenue and a diluted loss of $1.11 per share, despite modestly beating consensus. Liquidity remains substantial at $1,153.5 million, and…
Read full summary
Xenon continues to operate as a development-stage biotechnology company with $0 revenue and a diluted loss of $1.11 per share, despite modestly beating consensus. Liquidity remains substantial at $1,153.5 million, and management expects funding for at least the next 12 months, but nine-month losses widened 34.5% year over year to $323.5 million. The September 2026 pause in new MDD and BPD enrollment following neuropsychiatric adverse-event analysis adds significant clinical execution risk, while the filing provides no numeric financial guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.11
What stood out
-
EPS modestly beats despite no revenue
Diluted EPS was $1.11 per share below zero, versus the $1.15 loss consensus, a $0.04 beat or approximately 3.5%. Revenue remained $0, consistent with the company’s statement that it has not generated product-sale revenue.
-
Strong liquidity supports near-term runway
Cash and cash equivalents plus marketable securities totaled $1,153.5 million as of September 30, 2026. Management expects these resources to fund operating expenses and capital expenditures for at least the next 12 months.
-
Effective disclosure controls
The company reported nine-month net losses of $323.5 million in 2026 versus $240.6 million in 2025, a $82.9 million or 34.5% increase in losses. The accumulated deficit reached $1,568.9 million.
-
Controls assessed effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of September 30, 2026, and reported no changes in internal controls that materially affected, or were reasonably likely to materially affect, financial reporting.
-
Investment portfolio has rate sensitivity
Interest-rate exposure is material to the investment portfolio: a 100-basis-point unfavorable rate change would have reduced the fair value of marketable securities by approximately $6.4 million as of September 30, 2026.
What to watch
-
MDD and BPD enrollment pause
The company implemented a voluntary pause on new enrollment in ongoing major depressive disorder and bipolar disorder studies in September 2026 following analysis of certain neuropsychiatric adverse events. The filing warns that the pause could delay regulatory timelines or lead to program delays or discontinuation.
-
Rising losses and future funding needs
Xenon reported net losses of $323.5 million for the nine months ended September 30, 2026, compared with $240.6 million in the prior-year period, and states that losses are expected to increase as research, regulatory and potential commercialization activities expand.
-
PFIC status creates investor tax risk
The filing states that Xenon was a passive foreign investment company for the year ended December 31, 2025 and may be a PFIC in 2026. PFIC treatment can cause U.S. holders to face ordinary-income taxation and interest charges on gains and dividends.
Management's outlook
No quantitative revenue or EPS guidance was provided. The filing states that cash and cash equivalents and marketable securities as of September 30, 2026 are expected to fund operating expenses and capital expenditure requirements for at least the next 12 months.
Earlier filings 4
10-K · February 26, 2026
Xenon remains a late-stage neuroscience biopharma centered on azetukalner, with multiple Phase 3 programs progressing (X-TOLE2 enrollment complete at 380 patients and topline readout anticipated in the first half of…
10-Q · November 3, 2025
Xenon Pharmaceuticals reported a net loss of $90.9 million for Q3 2025, slightly worse than the $62.8 million loss in the comparable quarter last year. Revenue remains at $0, while EPS also declined, reflecting…
10-Q · August 8, 2024
Xenon reported a net loss of $57,924k for the three months ended June 30, 2024 (EPS -$0.75), widening vs. the prior-year quarter loss of $47,461k (EPS -$0.72). Operating expenses rose to $69,104k driven by higher R&D of…
Smart money in XENE
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every XENE trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.